blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1353666

EP1353666 - MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.05.2014
Database last updated on 29.07.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): TR		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
THE CLEVELAND CLINIC FOUNDATION
9500 Euclid Avenue
Cleveland, OH 44195 / US
[N/P]
Former [2013/11]For all designated states
The Cleveland Clinic Foundation
9500 Euclid Avenue
Cleveland, OH 44195 / US
Former [2003/43]For all designated states
THE CLEVELAND CLINIC FOUNDATION
9500 Euclid Avenue-WB3
Cleveland, OH 44195 / US
Inventor(s)01 / HAZEN, Stanley
31650 Gates Mills Boulevard
Pepper Pike, OH 44124 / US
02 / ZHANG, Renliang
23500 E. Silsby Road
Beachwood, OH 44122 / US
 [2013/11]
Former [2004/01]01 / HAZEN, Stanley
31650 Gates Mills Boulevard
Pepper Pike, OH 44124 / US
02 / ZHANG, Renliang
23500 E. Silsby Road
Beachwood, Ohio 44122 / US
Former [2003/43]01 / HAZEN, Stanley
31650 Gates Mills Boulevard
Pepper Pike, OH 44124 / US
02 / ZHANG, Renliang
2840 S. Moreland Boulevard, Apt. 7
Cleveland, OH 44120 / US
Representative(s)Brasnett, Adrian Hugh, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[N/P]
Former [2013/27]Brasnett, Adrian Hugh, et al
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS / GB
Former [2003/43]Brasnett, Adrian Hugh, et al
Mewburn Ellis York House 23 Kingsway
London WC2B 6HP / GB
Application number, filing date02718773.102.01.2002
[2003/43]
WO2002US00050
Priority number, dateUS20010259340P02.01.2001         Original published format: US 259340 P
US20010283432P12.04.2001         Original published format: US 283432 P
[2004/02]
Former [2003/43]US20010259340P02.01.2001
US20010283432P12.05.2001
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO02062207
Date:15.08.2002
Language:EN
[2002/33]
Type: A2 Application without search report 
No.:EP1353666
Date:22.10.2003
Language:EN
The application published by WIPO in one of the EPO official languages on 15.08.2002 takes the place of the publication of the European patent application.
[2003/43]
Type: B1 Patent specification 
No.:EP1353666
Date:03.07.2013
Language:EN
[2013/27]
Search report(s)International search report - published on:US31.10.2002
(Supplementary) European search report - dispatched on:EP17.02.2004
ClassificationIPC:C12Q1/28, A61K31/40
[2004/13]
CPC:
G01N33/573 (EP,US); A61K31/616 (EP,US); A61P9/00 (EP);
C12N1/28 (US); C12Q1/28 (EP,US); G16H10/40 (EP,US);
G16H50/30 (EP,US); G16Z99/00 (EP,US); C12Y111/01007 (EP,US);
G01N2333/908 (US); G01N2800/32 (EP,US); G01N2800/324 (US);
G01N2800/50 (US); G01N2800/52 (US); Y02A90/10 (EP,US) (-)
Former IPC [2003/43]A61K31/40
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2003/43]
TitleGerman:MYELOPEROXIDASE, EIN RISIKOINDIKATOR FÜR CARDIOVASKULARE KRANKHEITEN[2003/43]
English:MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE[2003/43]
French:LA MYELOPEROXYDASE, UN INDICATEUR DE RISQUE DES MALADIES CARDIO-VASCULAIRES[2013/11]
Former [2003/43]LA MYELOPEROXYDASE : UN INDICATEUR DE RISQUE DES MALADIES CARDIO-VASCULAIRES
Entry into regional phase31.07.2003National basic fee paid 
31.07.2003Search fee paid 
31.07.2003Designation fee(s) paid 
31.07.2003Examination fee paid 
Examination procedure29.07.2002Request for preliminary examination filed
International Preliminary Examining Authority: US
31.07.2003Examination requested  [2003/43]
19.05.2008Despatch of a communication from the examining division (Time limit: M06)
26.11.2008Reply to a communication from the examining division
15.02.2010Despatch of a communication from the examining division (Time limit: M06)
17.08.2010Reply to a communication from the examining division
24.09.2012Cancellation of oral proceeding that was planned for 25.09.2012
25.09.2012Date of oral proceedings (cancelled)
14.02.2013Communication of intention to grant the patent
23.05.2013Fee for grant paid
23.05.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.05.2008
Opposition(s)04.04.2014No opposition filed within time limit [2014/24]
Fees paidRenewal fee
26.01.2004Renewal fee patent year 03
20.01.2005Renewal fee patent year 04
27.01.2006Renewal fee patent year 05
29.01.2007Renewal fee patent year 06
25.01.2008Renewal fee patent year 07
30.01.2009Renewal fee patent year 08
25.01.2010Renewal fee patent year 09
25.01.2011Renewal fee patent year 10
25.01.2012Renewal fee patent year 11
25.01.2013Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT03.07.2013
BE03.07.2013
CY03.07.2013
TR03.07.2013
GR04.10.2013
PT04.11.2013
[2016/33]
Former [2014/18]AT03.07.2013
BE03.07.2013
CY03.07.2013
GR04.10.2013
PT04.11.2013
Former [2014/12]CY19.06.2013
AT03.07.2013
BE03.07.2013
GR04.10.2013
PT04.11.2013
Former [2014/10]CY19.06.2013
AT03.07.2013
BE03.07.2013
PT04.11.2013
Former [2014/09]AT03.07.2013
BE03.07.2013
PT04.11.2013
Former [2014/08]PT04.11.2013
Documents cited:Search[A]EP0389381  (SANOFI SA [FR]) [A] 1-22 * the whole document *;
 [E]WO0250550  (HENOGEN S A [BE], et al) [E] 1-22* the whole document *;
 [X]  - MARQUEZ LEAH A ET AL, "Kinetics of oxidation of tyrosine and dityrosine by myeloperoxidase compounds I and II: Implications for lipoprotein peroxidation studies", JOURNAL OF BIOLOGICAL CHEMISTRY, (1995), vol. 270, no. 51, ISSN 0021-9258, pages 30434 - 30440, XP002268582 [X] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.270.51.30434
 [X]  - SCHMITT DAVID ET AL, "Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum", BIOCHEMISTRY, (19991221), vol. 38, no. 51, ISSN 0006-2960, pages 16904 - 16915, XP002268583 [X] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1021/bi991623w
 [DX]  - ABU-SOUD HUSAM M ET AL, "Nitric oxide modulates the catalytic activity of myeloperoxidase", JOURNAL OF BIOLOGICAL CHEMISTRY, (20000225), vol. 275, no. 8, ISSN 0021-9258, pages 5425 - 5430, XP002268584 [DX] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.275.8.5425
International search[A]US5122534  (LOOSE LELAND D [US], et al);
 [A]US5889042  (MACLEAN DAVID B [US], et al);
 [YP]  - MERTENS, A. ET AL., "Oxidized LDL and HDL: antagonists in atherothrombosis", FASEB JOURNAL, (200110), vol. 15, no. 5, pages 2073 - 2084, XP002952171

DOI:   http://dx.doi.org/10.1096/fj.01-0273rev
 [Y]  - PODREZ, A. ET AL., "Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species", J. CLIN. INVEST., (200004), vol. 105, no. 8, pages 1095 - 1108, XP002952172

DOI:   http://dx.doi.org/10.1172/JCI8574
 [Y]  - MOMII, H. ET AL., "Inhibition of adhesion molecules markedly ameliorates cytokine-induced sustained mycocardial dysfunction in dogs in vivo", J. MOL. CELL CARDIOL., (1998), vol. 30, pages 2637 - 2650, XP002952173

DOI:   http://dx.doi.org/10.1006/jmcc.1998.0820
 [A]  - HONG, J.H. ET AL., "Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats", HYPERTENSION, (2002), vol. 38, pages 1044 - 1048, XP002952174

DOI:   http://dx.doi.org/10.1161/hy1101.095331
Examination   - HOLVOET P, "ENDOTHELIAL DYSFUNCTION, OXIDATION OF LOW-DENSITY LIPOPROTEIN, AND CARDIOVASCULAR DISEASE", THERAPEUTIC APHERESIS, BLACKWELL SCIENCE, MALDEN, MA, US, (19991101), vol. 3, no. 4, doi:10.1046/J.1526-0968.1999.00169.X, ISSN 1091-6660, pages 287 - 293, XP000874008

DOI:   http://dx.doi.org/10.1046/j.1526-0968.1999.00169.x
    - ZHANG RENLIANG ET AL, "ASSOCIATION BETWEEN MYELOPEROXIDASE LEVELS AND RISK OF CORONARY ARTERY DISEASE", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, (20011107), vol. 286, no. 17, doi:10.1001/JAMA.286.17.2136, ISSN 0098-7484, pages 2136 - 2142, XP009084422

DOI:   http://dx.doi.org/10.1001/jama.286.17.2136
by applicantEP0389381
 US6040147
    - MARQUEZ ET AL., J. BIO. CHEM., (1995), vol. 270, no. 51, pages 30434 - 30440
    - SCHMITT ET AL., BIOCHEMISTRY, (1999), vol. 38, no. 51, pages 16904 - 16915
    - ABU-SOUD ET AL., J. BIO. CHEM., (2000), vol. 275, no. 8, pages 5425 - 5430
    - MERTENS ET AL., FASEB J., (2001), vol. 15, no. 5, pages 2073 - 2084
    - PODREZ ET AL., J. CLIN. INVEST., (2000), vol. 105, no. 8, pages 1095 - 1108
    - HONG ET AL., HYPERTENSION, (2002), vol. 38, pages 1044 - 1048
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.